Sinotau is at the forefront of innovative radiopharmaceuticals, headquartered in Beijing, China, and with a global reach. Since 2014, Sinotau has been engaged in the research and development of targeted radiopharmaceuticals. The company operates modern, intelligent radiopharmaceutical production sites in Jiangsu, Guangdong, and Sichuan, along with an early discovery center in Shanghai and a branch in the United States. Sinotau has taken the lead in establishing a portfolio of targeted therapies and precision diagnostic radiopharmaceuticals for tumors, neurodegenerative diseases, and cardiovascular diseases. With over 20 novel products in various stages of development, Sinotau envisions the future guided by the mission “to invent radiopharmaceuticals for lives”. The company continues to invest in research and development, aiming to enhance the quality of life for patients and contribute to the advancement of China’s radiopharmaceutical sector.